Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
    Meeting Abstract

    Wong, W.; Sherman, E. J.; Kriplani, A.; Michel, L.; Zhi, I.; Hung, T. K. W.; Dunn, L.; Grewal, R. K.; Krishnamoorthy, G.; Ostrovnaya, I.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Intracranial response in patients (pts) with baseline (BL) brain metastases (BM) and extensive-stage (ES) small cell lung cancer (SCLC) treated with ifinatamab deruxtecan (I-DXd) in the IDeate-Lung01 study
    Meeting Abstract

    Johnson, M. L.; Simoes da Rocha, P. F.; Kim, Y. J.; Chen, Y.; Paz-Ares, L. G.; Girard, N.; Hann, C. L.; Nishio, M.; Ahn, M. J.; Qian, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)
    Meeting Abstract

    Rudin, C. M.; Salkeni, M. A.; Gutierrez, M.; Hayashi, H.; Thompson, J.; Arca, M.; Hirose, D.; Singh, J.; Turner, J.; Zhang, Y.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas
    Meeting Abstract

    Rosenbaum, E.; Ehrich, F.; Bradic, M.; Kelly, C. M.; Movva, S.; Chan, J.; Chi, P.; Banks, L.; Dickson, M.; Keohan, M. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated results of the RINGSIDE phase II trial and open-label extension of AL102 for treatment of desmoid tumors
    Meeting Abstract

    Kasper, B.; Gounder, M.; Chugh, R.; Singh, A.; Van Tine, B. A.; Andelkovic, V.; Choy, E.; Lewin, J.; Ratan, R.; Yovell, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Safety and efficacy with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received no prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
    Meeting Abstract

    Serrano, C.; Blay, J. Y.; Rutkowski, P.; Gelderblom, H.; Stacchiotti, S.; Falcon Gonzalez, A.; Desai, J.; Le Cesne, A.; Ferraresi, V.; Palmerini, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
    Meeting Abstract

    D'Amato, G.; Wagner, A. J.; Ganjoo, K. N.; Stacchiotti, S.; Gelderblom, H.; Ryan, C. W.; Palmerini, E.; Ravi, V.; Saleh, R.; Le Cesne, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Role of PIK3CA as a predictive biomarker in metastatic, imatinib-resistant GIST: A ct-DNA substudy of the VOYAGER trial
    Meeting Abstract

    Schardt, L. A.; Serrano, C.; Trent, J. C.; Krzeciesa, D.; Newberry, K.; Grassian, A.; Kang, Y. K.; Rutkowski, P.; Jones, R. L.; Heinrich, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Kelly, C. M.; Bradic, M.; Saunds, S.; Avutu, V.; Chan, J.; D'Angelo, S. P.; Dickson, M.; Gounder, M.; Keohan, M. L.; Movva, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma
    Meeting Abstract

    Babatunde, O.; Rosenbaum, E.; Kelly, C. M.; Desir-Camille, R.; Keohan, M. L.; Banks, L.; Avutu, V.; Chan, J.; Reed, D.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save